Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2020Cited by 1
756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)Jonathan W. Riess, Pilar Garrido, Luis Paz‐Ares et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2019Cited by 0